Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Account Payables (2023 - 2025)

NewAmsterdam Pharma's Change in Account Payables history spans 3 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 266.34% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $4.9 million, up 137.91%, while the annual FY2025 figure was $4.9 million, 137.91% up from the prior year.
  • Change in Account Payables for Q4 2025 was $5.3 million at NewAmsterdam Pharma, up from -$2.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $12.9 million in Q4 2023 and bottomed at -$9.2 million in Q3 2023.
  • The 3-year median for Change in Account Payables is -$1.3 million (2025), against an average of -$247416.7.
  • The largest YoY upside for Change in Account Payables was 266.34% in 2025 against a maximum downside of 219.11% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $12.9 million in 2023, then crashed by 124.79% to -$3.2 million in 2024, then soared by 266.34% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Change in Account Payables are $5.3 million (Q4 2025), -$2.3 million (Q3 2025), and -$391000.0 (Q2 2025).